Study of PF-06940434 in Patients With Advanced or Metastatic Solid Tumors.

Back to Search
Print
Bookmark Trial

NCT04152018

Last updated date
Back to Search
Print
Bookmark Trial
FOR MORE INFORMATION
Study Location
Seattle Cancer Care Alliance
Seattle, Washington, 98109, United States
See other locations
Contact
1-800-718-1021
[email protected]
Related Links

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center

1-800-718-1021

By email

Contact

[email protected]

Call Now

Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Squamous Cell Carcinoma of the Head and Neck, Renal Cell Carcinoma, Ovarian Cancer, Gastric Cancer, Esophageal Cancer, Lung Squamous Cell Carcinoma, Pancreatic Cancer, Bile Duct Cancer, Endometrial Cancer, Melanoma Cancer, Urothelial Cancer
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18 + years
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Histological or cytological diagnosis of SCCHN, RCC (clear cell and papillary cell), ovarian, gastric, esophageal (adeno and squamous), lung squamous cell, pancreatic and biliary duct, endometrial, melanoma, or urothelial cancer.

- Adequate bone marrow, kidney and liver function.

- Performance status of 0 or 1.

Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details


- Participant disease status is suitable for local therapy administered with curative
intent.


- Hypertension that cannot be controlled by medications.

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

Call Now

TRY A NEW SEARCH

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Advanced Search

Based on your search, you may also be interested in

Squamous Cell Carcinoma of the Head and Neck, Renal Cell Carcinoma, Ovarian Cancer, Gastric Cancer, Esophageal Cancer, Lung Squamous Cell Carcinoma, Pancreatic Cancer, Bile Duct Cancer, Endometrial Cancer, Melanoma Cancer, Urothelial CancerStudy of PF-06940434 in Patients With Advanced or Metastatic Solid Tumors.
NCT04152018
  1. Seattle, Washington
  2. Seattle, Washington
  3. Scottsdale, Arizona
  4. Scottsdale, Arizona
  5. Los Angeles, California
  6. Los Angeles, California
  7. Los Angeles, California
  8. Creve Coeur, Missouri
  9. Saint Louis, Missouri
  10. Saint Louis, Missouri
  11. Saint Louis, Missouri
  12. Saint Louis, Missouri
  13. Saint Peters, Missouri
  14. Houston, Texas
  15. San Antonio, Texas
  16. Seattle, Washington
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Advanced Information
Descriptive Information
Brief Title  ICMJE Study of PF-06940434 in Patients With Advanced or Metastatic Solid Tumors.
Official Title  ICMJE A PHASE 1 STUDY TO EVALUATE THE SAFETY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF ESCALATING DOSES OF PF-06940434 IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS
Brief Summary Open-label, multi-center, non-randomized, multiple dose, safety, tolerability, pharmacokinetic, and pharmacodynamics and clinical activity study of PF-06940434 in patients with SCCHN (Squamous Cell Carcinoma of the Head and Neck), renal cell carcinoma (RCC - clear cell and papillary), ovarian, gastric, esophageal, esophageal (adeno and squamous), lung squamous cell, pancreatic and biliary duct, endometrial, melanoma and urothelial tumors. This study contains two parts, single agent dose escalation (Part 1A), dose finding of PF 06940434 in combination with anti-PD-1 (Part 1B), biopsy cohorts with monotherapy lead-in at the maximum tolerated dose (MTD) or maximum administered dose (MAD), followed by combination of anti-PD-1 [PF-06801591] (Part 1C) followed by dose expansion (Part 2). Part 2 Dose Combination Expansion will enroll participants into 2 cohorts at doses determined from Part 1B in order to further evaluate the safety of PF-06940434 in combination with anti-PD-1.
Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 1
Study Design  ICMJE Allocation: Non-Randomized
Intervention Model: Sequential Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE
  • Squamous Cell Carcinoma of the Head and Neck
  • Renal Cell Carcinoma
  • Ovarian Cancer
  • Gastric Cancer
  • Esophageal Cancer
  • Lung Squamous Cell Carcinoma
  • Pancreatic Cancer
  • Bile Duct Cancer
  • Endometrial Cancer
  • Melanoma Cancer
  • Urothelial Cancer
Intervention  ICMJE
  • Drug: PF-06940434
    PF-06940434 is given intravenously (IV) every 2 weeks in a 28 day cycle. Multiple dose levels will be evaluated
  • Drug: PF-06801591
    PF-06801591 will be administered subcutaneously on Day 1 of each 28 day cycle.
    Other Name: Anti-PD-1
Study Arms  ICMJE
  • Experimental: Dose Escalation
    Single Agent Dose Escalation
    Intervention: Drug: PF-06940434
  • Experimental: Dose Finding Anti-PD-1 Combination 1
    Part 1B PF-06940434 plus anti-PD-1
    Interventions:
    • Drug: PF-06940434
    • Drug: PF-06801591
  • Experimental: Dose Finding Anti-PD-1 Combination 2
    Part 1C PF-06940434 plus anti-PD-1
    Interventions:
    • Drug: PF-06940434
    • Drug: PF-06801591
  • Experimental: Dose Expansion Arm A
    PF-06940434 with anti-PD-1 in SCCHN
    Interventions:
    • Drug: PF-06940434
    • Drug: PF-06801591
  • Experimental: Dose Expansion Arm B
    PF-06940434 with anti-PD-1 in RCC
    Interventions:
    • Drug: PF-06940434
    • Drug: PF-06801591
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Recruiting
Estimated Enrollment  ICMJE
 (submitted: November 2, 2019)		104
Original Estimated Enrollment  ICMJE Same as current
Estimated Study Completion Date  ICMJE March 19, 2024
Estimated Primary Completion Date March 19, 2024   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Histological or cytological diagnosis of SCCHN, RCC (clear cell and papillary cell), ovarian, gastric, esophageal (adeno and squamous), lung squamous cell, pancreatic and biliary duct, endometrial, melanoma, or urothelial cancer.
  • Adequate bone marrow, kidney and liver function.
  • Performance status of 0 or 1.

Exclusion Criteria:

  • Participant disease status is suitable for local therapy administered with curative intent.
  • Hypertension that cannot be controlled by medications.
Sex/Gender  ICMJE
Sexes Eligible for Study:All
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE
Contact: Pfizer CT.gov Call Center1-800-718-1021[email protected]
Listed Location Countries  ICMJE United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT04152018
Other Study ID Numbers  ICMJE C3891001
2020-004009-29 ( EudraCT Number )
Has Data Monitoring Committee No
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement  ICMJE
Plan to Share IPD:No
Plan Description:Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/d….
Responsible Party Pfizer
Study Sponsor  ICMJE Pfizer
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Director:Pfizer CT.gov Call CenterPfizer
PRS Account Pfizer
Verification Date January 2021

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP